Literature DB >> 32129687

Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.

Joanna Robles1, Vahakn S Keskinyan2, Matthew Thompson3, Joseph T Davis4, David Van Mater1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32129687      PMCID： PMC7367760          DOI： 10.1080/08880018.2020.1735591

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


× No keyword cloud information.
  21 in total

1.  Sorafenib for Advanced and Refractory Desmoid Tumors.

Authors:  Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses.

Authors:  Marry H Nieuwenhuis; Mariel Casparie; Lisbeth M H Mathus-Vliegen; Olaf M Dekkers; Pancras C W Hogendoorn; Hans F A Vasen
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

Review 3.  Desmoid-Type Fibromatosis: Evolving Treatment Standards.

Authors:  Marco Fiore; Andrea MacNeill; Alessandro Gronchi; Chiara Colombo
Journal:  Surg Oncol Clin N Am       Date:  2016-08-05       Impact factor: 3.495

4.  Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial.

Authors:  Stephen X Skapek; William S Ferguson; Linda Granowetter; Meenakshi Devidas; Antonio R Perez-Atayde; Louis P Dehner; Fredric A Hoffer; Roseanne Speights; Mark C Gebhardt; Gary V Dahl; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

5.  Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.

Authors:  AeRang Kim; Eva Dombi; Kathleen Tepas; Elizabeth Fox; Staci Martin; Pamela Wolters; Frank M Balis; Nalini Jayaprakash; Baris Turkbey; Naira Muradyan; Peter L Choyke; Alyssa Reddy; Bruce Korf; Brigitte C Widemann
Journal:  Pediatr Blood Cancer       Date:  2012-09-07       Impact factor: 3.167

6.  Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.

Authors:  Stephen X Skapek; James R Anderson; D Ashley Hill; David Henry; Sheri L Spunt; William Meyer; Simon Kao; Fredric A Hoffer; Holcombe E Grier; Douglas S Hawkins; R Beverly Raney
Journal:  Pediatr Blood Cancer       Date:  2012-12-31       Impact factor: 3.167

7.  Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis.

Authors:  Stefano Signoroni; Milo Frattini; Tiziana Negri; Elisa Pastore; Elena Tamborini; Paola Casieri; Marta Orsenigo; Luca Da Riva; Paolo Radice; Paola Sala; Alessandro Gronchi; Lucio Bertario; Marco A Pierotti; Silvana Pilotti
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

8.  Toward Observation as First-line Management in Abdominal Desmoid Tumors.

Authors:  Sally M Burtenshaw; Amanda J Cannell; Edward D McAlister; Saquib Siddique; Rita Kandel; Martin E Blackstein; Carol J Swallow; Rebecca A Gladdy
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

Review 9.  Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor.

Authors:  Keith M Skubitz
Journal:  Mayo Clin Proc       Date:  2017-06       Impact factor: 7.616

10.  Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG).

Authors:  Bernd Kasper; Viktor Gruenwald; Peter Reichardt; Sebastian Bauer; Geraldine Rauch; Ronald Limprecht; Michaela Sommer; Antonia Dimitrakopoulou-Strauss; Lothar Pilz; Florian Haller; Peter Hohenberger
Journal:  Eur J Cancer       Date:  2017-03-08       Impact factor: 9.162
View more
  2 in total

1.  Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System.

Authors:  Ramzi Shawahna; Ahed Zyoud; Aseel Haj-Yahia; Raheek Taya
Journal:  AAPS PharmSciTech       Date:  2021-03-01       Impact factor: 3.246

2.  Desmoid fibromatosis in the pharyngeal wall: A case report and literature review.

Authors:  Katharina Geisenhainer; Daniela Klenke; Norman Moser; Oliver Kurbad; Felix Bremmer; Philipp Kauffmann; Henning Schliephake; Phillipp Brockmeyer
Journal:  Clin Case Rep       Date:  2022-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.